As previously mentioned, in addition to endogenous cell death pathways [81], almost all tumor-targeted therapeutic strategies ultimately activate one of the body’s most powerful immune killing mechanisms: the activation of CD8+ T cell cytotoxicity [82, 83]. Here, CD8A is linked to neoplasm.